疾病早期进展作为慢性淋巴细胞白血病生存的预测因素
研究纳入2010至2014年Connect CLL注册研究中829例接受一线治疗的慢性淋巴细胞白血病患者,按疾病进展时间分为早期进展(治疗开始后<2年)、晚期进展(≥2年)和无进展三组。中位随访48.8个月,早期进展组总生存劣于其他组(风险比3.6,95%置信区间2.6-5.1,P<.01),提示一线治疗后2年内早期进展是总生存不良的稳健临床预后因素。
要点
- 中位随访48.8个月,早期进展209例(25.2%),晚期进展162例(19.5%),无进展458例(55.3%)。
- 早期进展组总缓解率53%,低于晚期进展组80%和无进展组84%。
- 早期进展与更差总生存相关(风险比3.6,95%置信区间2.6-5.1,P<.01)。
核心结论
- 一线治疗后2年内早期进展是慢性淋巴细胞白血病患者总生存不良的稳健临床预后因素。
研究设计与样本
- 研究为队列研究,纳入2010至2014年Connect CLL注册研究中829例接受一线治疗的合格慢性淋巴细胞白血病患者。
主要发现
- 中位随访48.8个月,早期进展209例(25.2%),晚期进展162例(19.5%),无进展458例(55.3%)。
- 早期进展组较晚期进展组和无进展组年龄更大,且对相似一线治疗方案的反应更差(总缓解率:早期进展组53% vs 晚期进展组80% vs 无进展组84%)。
- 早期进展组不良风险细胞遗传学(del[11q]/del[17p])比例高于无进展组(34% vs 20%;P = .04)。
- 早期进展与所有患者的总生存不良相关(风险比3.6;95%置信区间2.6-5.1;P < .01),在接受氟达拉滨、环磷酰胺联合利妥昔单抗以及苯达莫司汀联合利妥昔单抗治疗的患者中亦相关(P < .05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chemoimmunotherapy for chronic lymphocytic leukemia (CLL) promotes clonal evolution of aggressive clones, which in some patients may lead to early progression of disease (POD). We studied the prognostic value of early POD in a cohort of patients with CLL enrolled between 2010 and 2014 in the Connect CLL Registry. Overall, 829 eligible patients receiving first-line therapy were categorized into 3 groups: early POD (progression <2 years after treatment initiation), late POD (progression ≥2 years after treatment initiation), and no POD as of 1 May 2017. Baseline demographics, treatment characteristics, and overall survival (OS) were analyzed. Logistic regression models identified independent predictors of early POD; Cox regression models were used to evaluate the risk of early POD. With a median follow-up of 48.8 months, 209 (25.2%), 162 (19.5%), and 458 (55.3%) patients had early, late, and no POD, respectively. Patients with early POD were older and had inferior response to similar first-line treatment regimens vs late and no POD groups (overall response rate: 53% vs 80% vs 84%). Patients with early POD were more likely to have unfavorable-risk cytogenetics (del[11q]/del[17p]) than patients with no POD (34% vs 20%; P = .04). Early POD was associated with an inferior OS across all patients (hazard ratio, 3.6; 95% confidence interval, 2.6-5.1; P < .01) and in patients treated with fludarabine, cyclophosphamide plus rituximab, and bendamustine plus rituximab (P < .05). Early POD within 2 years of first-line therapy is a robust clinical prognostic factor for inferior OS in patients with CLL. The Connect CLL Registry was registered at www.clinicaltrials.gov as #NCT01081015.
引用
- Ahn IE, Farber CM, Davids MS, et al. Early progression of disease as a predictor of survival in chronic lymphocytic leukemia. Blood Adv. 2017. PMID: 29296893. doi:10.1182/bloodadvances.2017011262
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。